2023 World Conference on Lung Cancer (Posters)-P2.17. Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial

P2.17. Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial - PDF(Abstract)

Back to course

Pdf Summary

This abstract presents the findings of a study conducted on patients with small cell lung cancer (SCLC) who experienced relapse and were treated with platinum-based therapy. The study aimed to determine the efficacy of platinum rechallenge after initial treatment with lurbinectedin (L)/doxorubicin (DOX) or topotecan/CAV.<br /><br />The study included 208 patients in the L/DOX arm and 205 patients in the topotecan/CAV arm, all of whom had a chemotherapy-free interval (CTFI) of at least 90 days. Of these patients, 28 in the L/DOX arm and 30 in the topotecan/CAV arm received immediate platinum rechallenge after discontinuation of the study treatment.<br /><br />The results showed that patients in the L/DOX arm who received further platinum treatment had higher overall response rates (ORR) and longer median durations of response (DoR), progression-free survival (PFS), and overall survival (OS) compared to those in the topotecan/CAV arm. Although the median PFS was similar in both arms during platinum rechallenge, the median OS was longer in the L/DOX arm.<br /><br />These findings suggest that the efficacy of platinum rechallenge after treatment with L/DOX is comparable to that reported in previous studies. The longer OS observed in the L/DOX arm could be attributed to the longer median PFS achieved with this treatment. The study concludes that giving lurbinectedin as a second-line treatment for platinum-sensitive relapsed SCLC patients does not hinder the effectiveness of subsequent platinum rechallenge and may extend the platinum-free interval, ultimately improving patient survival.<br /><br />In summary, this study provides evidence that platinum rechallenge following treatment with lurbinectedin/doxorubicin is effective in platinum-sensitive relapsed SCLC patients and may lead to improved survival outcomes.

Asset Subtitle

Jose Antonio Lopez-Vilariño

Meta Tag

Speaker Jose Antonio Lopez-Vilariño

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

small cell lung cancer

SCLC

relapse

platinum-based therapy

platinum rechallenge

lurbinectedin

doxorubicin

topotecan

chemotherapy-free interval

overall survival